William Blair Estimates Amedisys’ Q1 Earnings (NASDAQ:AMED)

Amedisys, Inc. (NASDAQ:AMED) – Stock analysts at William Blair dropped their Q1 2025 earnings per share estimates for Amedisys in a research note issued on Thursday, February 27th. William Blair analyst M. Larew now expects that the health services provider will post earnings of $0.98 per share for the quarter, down from their prior estimate of $1.01. The consensus estimate for Amedisys’ current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys’ Q2 2025 earnings at $1.33 EPS, Q3 2025 earnings at $1.05 EPS, Q4 2025 earnings at $1.08 EPS and FY2025 earnings at $4.45 EPS.

Separately, Stephens reaffirmed an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Wednesday, February 12th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Amedisys has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Up 0.3 %

Shares of NASDAQ AMED opened at $92.00 on Friday. Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of 36.51, a PEG ratio of 1.78 and a beta of 0.73. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock’s 50-day simple moving average is $91.41 and its 200-day simple moving average is $93.18.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $598.05 million for the quarter, compared to analysts’ expectations of $602.38 million.

Hedge Funds Weigh In On Amedisys

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Amedisys by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider’s stock worth $291,992,000 after purchasing an additional 10,817 shares in the last quarter. Pentwater Capital Management LP boosted its stake in Amedisys by 178.3% in the fourth quarter. Pentwater Capital Management LP now owns 1,180,000 shares of the health services provider’s stock valued at $107,132,000 after acquiring an additional 756,000 shares during the period. Westchester Capital Management LLC boosted its stake in Amedisys by 9.5% in the third quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock valued at $107,976,000 after acquiring an additional 97,476 shares during the period. Norges Bank acquired a new position in Amedisys in the fourth quarter valued at approximately $83,061,000. Finally, Alpine Associates Management Inc. boosted its stake in Amedisys by 3.2% in the fourth quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider’s stock valued at $80,632,000 after acquiring an additional 27,403 shares during the period. 94.36% of the stock is currently owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.